Please ensure Javascript is enabled for purposes of website accessibility

Why Medivation, Puma Biotechnology, and Synnex Slumped Today

By Dan Caplinger - Mar 29, 2016 at 6:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even though the broader market climbed, these stocks missed out. Find out why.

Image source: Medivation and Astellas.

Tuesday featured broad-based gains from major stock market indexes, reflecting positive sentiment stemming from comments that Fed Chair Janet Yellen made about the U.S. economy and the central bank's likely course of future action with respect to monetary policy. Going into the chair's comments, the market was slightly down, but Yellen suggested the Federal Reserve might be slower in implementing future rate increases than investors had expected. That sparked an afternoon rally that sent the Dow up nearly 100 points. However, some stocks missed out on the gains, and Medivation (MDVN), Puma Biotechnology (PBYI 4.51%), and Synnex (SNX -0.63%) were among the relatively small number of decliners in Tuesday's market action.

Medivation fell 6% after the maker of prostate cancer drug Xtandi attracted the attention of certain influential members of Congress, including presidential candidate Bernie Sanders. A course of treatment for Medivation's drug carries a six-figure price tag in the U.S., but other countries have negotiated lower prices for Xtandi, and lawmakers would like to seek ways to force the company to cut its price domestically as well. Medivation partner Astellas responded that most patients with private insurance or Medicare pay minimal out-of-pocket costs, and the manufacturer provides Xtandi free for many eligible uninsured or underinsured individuals who need the treatment. Nevertheless, the company is just the latest of several drug companies that have come under fire for high-priced treatments, and it's unclear whether the political climate will improve or worsen in the months ahead.

Puma Biotechnology plunged 21% following news Monday night that the company would delay its new drug application for its prospective extended adjuvant breast-cancer treatment neratinib until the middle of the year. Puma said it had discussed preclinical data with the FDA along with Phase 2 and 3 trial data for neratinib, and the FDA's response included a request to amend certain analysis under the trials to incorporate regulatory recommendations. Even though the request doesn't really call into question the positive results the trials have shown so far, investors are clearly impatient and disappointed that Puma won't be able to meet its goal of filing for approval for neratinib during the first quarter.

Finally, Synnex dropped 7%. The business-process services company reported its fiscal first-quarter results Monday night, and investors reacted negatively to slight declines of 2% in revenue and 6% in adjusted net income. Adverse foreign currency movements accounted for much of the sales decline in the company's technology services unit. However, Synnex's guidance for the fiscal second quarter was well below what investors were looking to see, including sales expectations of $3.25 billion to $3.35 billion and adjusted earnings of $1.27 to $1.33 per share. Despite CEO Kevin Murai's assertions that Synnex is poised to capitalize on opportunities for growth, investors want Synnex to show them that growth before they're willing to send the stock back toward its all-time highs.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Medivation, Inc. Stock Quote
Medivation, Inc.
SYNNEX Corporation Stock Quote
SYNNEX Corporation
$90.35 (-0.63%) $0.57
Puma Biotechnology, Inc. Stock Quote
Puma Biotechnology, Inc.
$2.78 (4.51%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.